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20  12 His48-positive cells/glomerulus vs. 3.7  1.3 His48-Effects of 1,25(OH)2D3 in experimental mesangial proliferative
positive cells/glomerulus, P 0.001), and monocyte accumula-nephritis in rats.
tion (day 7, 4.9  2.9 ED1-positive cells/glomerulus vs. 2.8 Background. 1,25-Dihydroxyvitamin D3 [1,25(OH)2D3], the
2.9 ED1-positive cells/glomerulus, P  0.05), and attenuatedactive form of vitamin D3, is a potent immunomodulatory agent
glomerular cells proliferation (day 7, 13  3.2 PCNA-positiveon several cell types such as monocytes and mesangial cells.
Recruitment of inflammatory cells, as well as stimulation of cells/glomerulus vs. 9.4  3 PCNA-positive cells/glomerulus,
resident cells and mesangial matrix accumulation are key fea- P 0.01). Apoptosis showed a biphasic behavior with an early
tures of various experimental and human glomerular diseases. peak at day 4 in the anti-Thy-1.1 group (2.3  2.2 TUNEL-
Here we show that 1,25(OH)2D3 attenuates the morphologic positive cells/glom) related to cellular lysis and a late peak at
and functional alterations in anti-Thy-1.1. nephritis, an experi- day 14 related to the recovery phase.
mental model of mesangial proliferative glomerulonephritis. Conclusions. 1,25(OH)2D3 can reduce glomerular hypercel-
Methods. The anti-Thy-1.1 group (group I) comprised 24 lularity, inflammatory infiltration in anti-Thy-1.1 nephritis, pre-
rats that at day 0 received 0.5 mL of saline containing 400 g serving the apoptotic response of the reparative phase.
of monoclonal antibodies (mAb) anti-Thy-1.1 IgG. The anti-
Thy-1.1 treated with 1,25(OH)2D3 group (group II) were 24 rats
given 1,25(OH)2D3 at the dose of 25 ng/100 g body wt/day,
Recruitment of inflammatory cells, as well as stimula-from day 3 to day 14. At day 0, the rats received 400 g of
anti-Thy-1.1 monoclonal IgG. The control group (group III) tion of resident cells and accumulation of mesangial ma-
comprised 12 rats injected with vehicle alone; the control group trix are key features of various experimental and human
treated with 1,25(OH)2D3 (group IV)—12 rats were given glomerular diseases. Mesangial cell proliferation and ma-1,25(OH)2D3 as in group II without mAb administration. Pro- trix accumulation may contribute to the development ofteinuria and urinary interleukin-6 excretion were measured
glomerulosclerosis independently of the underlying pri-daily. Blood urea nitrogen and creatinine, creatinine clearance,
calcium, and phosphate were measured at days 0, 4, 7, and mary disease [1, 2]. 1,25(OH)2D3 was shown to affect cell
14. In addition to conventional periodic acid-Schiff staining, growth and differentiation from a variety of tissues. Thus,
binding of anti-Thy-1.1 IgG and C3b complement fraction, apart from its classic role in bone and mineral metabo-His48- and ED1–positive cells were studied by immunofluo-
lism, 1,25(OH)2D3 inhibits cell proliferation and pro-rescence. Mesangial proliferation was studied by the proliferat-
motes cell differentiation [3, 4]. The effects on lympho-ing cell nuclear antigen (PCNA) technique. Apoptosis was
evaluated by the TUNEL assay. cyte and macrophage functions are exerted by binding
Results. The anti-Thy-1.1 treated with 1,25(OH)2D3 group of 1,25(OH)2D3 to vitamin D receptors expressed onversus the anti-Thy-1.1 alone group showed a significant reduc-
monocytes and on activated but not on resting T lympho-tion in urinary protein (at day 7, 424  228 vs. 66  30 mg/mg
cytes [5, 6]. Several lines of evidence indicate an immuno-urinary creatinine, P  0.02) and interleukin-6 excretion (at
day 3, 537  360 pg/mL vs. 110  34 pg/mg urinary creatinine, suppressive activity of 1,25(OH)2D3 [7, 8]. It has been
P  0.015), reduced glomerular diameters (at day 7, 283  38 recently shown that dendritic cells are the major target of
vs. 261  48 m, P  0.01), decreased neutrophil (at day 4, 1,25(OH)2D3-induced immunosuppressive activity since
1,25(OH)2D3 inhibits differentiation, maturation, and
survival of these cells, leading to impaired alloreactiveKey words: vitamin D3, anti-Thy-1.1 nephritis, apoptosis, interleukin-6,
inflammation, mesangial matrix. T-cell activation [9]. Moreover, 1,25(OH)2D3 inhibits the
production of monocytes-derived cytokines such as in-
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derived ammonium sulfate-precipitated monoclonal an-
tibodies (mAb) anti-Thy-1.1 IgG (Cederlane, Ontario,
Canada).
Anti-Thy-1.1 treated with 1,25(OH)2D3 group (group II).
From day 3 to day 14, 24 rats were given 1,25(OH)2D3
(Calcijex; Abbott, North Chicago, IL, USA) at the dose
of 25 ng/100 g body wt/day. At day 0, rats received 0.5 mL
of saline containing 400 g of ascites-derived ammonium
sulfate-precipitated mAb anti-Thy-1.1 IgG.
Fig. 1. Rats were randomly allotted to one of the four groups of treat-
Control group (group III). At day 0, 12 rats werement. (1) The anti-Thy-1.1 group. At day 0, 24 rats received an IV
injected intravenously with 0.5 mL of vehicle.bolus of anti-Thy-1.1 IgG monoclonal antibody (mAb). (2) Anti-Thy-1.1
treated with 1,25(OH)2D3. From day 3 to day 14, 24 rats were given Control group treated with 1,25(OH)2D3 (group IV).1,25(OH)2D3 at the dose of 25 ng/100g body wt/day. At day 0, they From day 3 to day 14, 12 rats were given 1,25(OH)2D3received anti-Thy-1.1 IgG mAb. (3) Control group. At day 0, 12 rats
at the dose of 25 ng/100 g body wt/day. At day 0, theywere injected intravenously with 0.5 mL of vehicle. (4) Control group
treated with 1,25(OH)2D3. From day 3 to day 14, 12 rats were given received 0.5 mL of vehicle.
1,25(OH)2D3 at the dose of 25 ng/100g body wt/day. At day 0, they Anti-Thy-1 antibody and vehicle were given by intra-received 0.5 mL of vehicle. Six rats of each group were sacrificed for
femoral venous injection, whereas 1,25(OH)2D3 was ad-the morphological studies where indicated by the arrows.
ministered subcutaneously by osmotic minipump (Charles
River).
of T cells and their release of cytokines such as IL-2 and Measurements
interferon- are also suppressed by 1,25(OH)2D3 [11]. Twenty-four–hour urine samples were collected with
We recently reported that treatment with 1,25(OH)2D3 the aid of metabolic cages.
inhibits in a dose-dependent manner the production of Proteinuria was measured daily by using the Bio-Rad
both IL-1 and TNF- by lymphomonocytes of patients Protein Assay (Bio-Rad Laboratories GmbH, Mu¨nchen,
with chronic renal failure [12]. In a renal cell carcinoma Germany) and bovine serum albumin (Sigma Chemical
line, Nagakura et al showed a dose-dependent inhibition of Co., St. Louis, MO, USA) as a standard. Blood samples
proliferation by 1,25(OH)2D3 [13]. Moreover, 1,25(OH)2D3 for urea, creatinine, calcium, phosphate were drawn from
diminished proliferation of cultured mouse [14] and hu- conscious rat via the caudal vein at days 3, 0, 4, 7, and
man mesangial cells [15], and secretion of transform- 14 using ethylenediaminetetraacetic acid (EDTA) as the
ing growth factor- (TGF-) in both human mesangial anticoagulant, and the plasma was stored below 20	C.
cells and in a proximal tubular cell line [16]. In vivo, Urinary calcium was determined daily. Blood and uri-
1,25(OH)2D3 was shown to reduce proteinuria in active nary samples were analyzed using an autoanalyzer
Heymann nephritis [17] and renal cell proliferation and (Beckman Instruments GmbH, Munchen, Germany).
glomerular growth, glomerulosclerosis, and albuminuria Body weight was measured at regular intervals.
in a model of subtotal nephrectomy [18].
IL-6 urinary activityThe aim of the present study was to investigate the
effects of 1,25(OH)2D3 in a model of proliferative glo- Interleukin-6 activity was examined daily in the urine
merulonephritis induced in the rat by anti-Thy-1.1 anti- using a highly sensitive specific anti-rat enzyme-linked
bodies. immunosorbent assay (ELISA; Biosource, Los Angeles,
CA, USA) with an intra-assay and interassay variability
of lower than 5%. The lower detection limit of the assayMETHODS
was 20 pg/mL. No cross-reactivity with recombinant
Experimental design TNF-, TNF-, IL-1 and IL-1, IL-2, IL-3, and IL-4
Animals. Eight-week-old female Wistar rats (Charles was observed when these cytokines were added to blank
River, Calco, Italy) weighing 160 to 200 g were housed samples in concentrations of up to 50 ng/mL.
in single metabolic cages at constant room temperature
Morphologic studies(20	C) and humidity (75%) under a controlled light/dark
cycle. The rats were fed a standard chow diet and animals At the end of the experiment, the kidneys were re-
had free access to drinking water. Experiments were moved: One half was snap-frozen in liquid nitrogen-
performed in accordance to the guidelines of our local cooled isopentane and stored at 70	C, and the other
ethical committee. Rats were randomly allotted to one half was fixed in 10% neutral-buffered formalin and em-
of the four following groups of treatment (Fig. 1). bedded in paraffin.
Anti-Thy-1.1 group (group I). Twenty-four rats at day To investigate glomerular morphology, sections of 3
m of thickness were stained with periodic acid-Schiff0 received 0.5 mL of saline containing 400 g of ascites-
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Fig. 2. Protein excretion in the four groups
of rats before the injection of anti-Thy-1.1
antibodies. Symbols are: () anti-Thy-1.1; ()
anti-Thy-1.1 
 vitamin D3; () controls; ()
controls 
 vitamin D3. (A) Compared with
control rats, anti-Thy-1.1 nephritic rats (anti-
Thy-1.1) demonstrated frank proteinuria from
days 2 to 14 [ANOVA with Student-Neu-
mann-Keul’s multicomparison t test was per-
formed: *P 0.05 vs. control group; §P 0.05
vs. anti-Thy-1.1 
 1,25(OH)2D3]. In nephritic
rats in which 1,25(OH)2D3 was administered
[anti-Thy-1.1
 1,25(OH)2D3], a significant re-
duction of proteinuria was detected. The en-
hanced IL-6 urinary excretion (B) observed
in nephritic rats at days 2, 3, 4, and 7 was
significantly inhibited by 1,25(OH)2D3 admin-
istration.
(PAS) reagent and hematoxylin and eosin (HE). For at room temperature to block endogenous peroxidase.
Sections were subsequently blocked with 10% normaleach rat, all glomerular cross-sections present in a speci-
men were evaluated. Glomerular diameters of each kid- goat antiserum for 30 minutes at room temperature, and
the primary antibodies were added followed by incuba-ney in a cross-section were measured by a graduated
lens (250). tion at 37	C for two hours. Then sections were washed
three times in PBS for 10 minutes. Anti-PCNA–treatedThree micrometer thick frozen sections were cut and
fixed in acetone, washed with phosphate-buffered saline section were incubated with streptavidin-peroxidase for
10 minutes, and then the reaction was detected with(PBS), incubated with primary antibodies against anti-
Thy-1.1 antibody, anti-rat C3 (ED11 antigen, MCA733 peroxidase substrate containing diaminobenzidine chro-
mogen (DAB). Anti-ED1–treated sections were incu-Serotec Ltd., UK) and anti-rat granulocytes His48 anti-
gen (MCA967 Serotec Ltd.). Then the slides were incu- bated with a biotinylated anti-mouse secondary antibody
(100 L for 20 min at room temperature); then a sub-bated with FITC-conjugated antibodies (Sigma, MA,
USA) specific for each primary antibody. strate-chromogen mixture containing 3-amino-9-ethyl-
carbazole (AEC) was added to each section (10 min atThe slides were examined by a fluorescence micro-
scope (Lietz, Wetzlar, Germany). room temperature).
Finally, all sections were counterstained with 100 LImmunohistochemical staining for proliferating glo-
merular cells with a biotinylated mouse antiproliferating hematoxylin. For the negative controls, the specific anti-
bodies were omitted.cell nuclear antigen (PCNA; Zymed, South San Fran-
cisco, CA, USA) and for infiltrating monocytes with a To measure DNA nicking, a marker of apoptosis,
the TUNEL assay (In situ cell death detection kit-POD;mouse anti-rat ED1-mAB (MCA341R; Serotec). Briefly,
3m renal section were microwaved in 0.01 mol/L citrate Roche Diagnostics S.p.A., Italy) was performed on for-
malin-fixed tissue. Terminal deoxynucleotidyl transferasebuffer, pH 6.0, for two 10-minute periods at 600 W to
retrieve the antigens. The sections were then treated (TdT) was omitted from the nucleotide mixture as a
negative control. Tissue sections treated with DNAse towith 3% hydrogen peroxide in methanol for 10 minutes
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Table 1. Renal function, serum calcium and phosphate
Day 0 Day 4 Day 7 Day 14
BUN mg/dL
Anti-Thy-1.1 6012 8510a 6113 6515
Controls 427 385 548 507
Anti-Thy-1.1 
 vitamin D3 458 5210 509 5613
Vitamin D3 5012 5410 4911 5311
Creatinine mg/dL
Anti-Thy-1.1 0.600.12 1.30.15a 0.960.13 1.150.2
Controls 0.650.2 0.70.3 0.780.21 0.80.3
Anti-Thy-1.1 
 Vitamin D3 0.500.3 0.920.3 0.750.2 0.700.2
Vitamin D3 0.500.2 0.750.3 0.80.11 0.90.3
Calcium mg/dL
Anti-Thy-1.1 11.200.52 11.610.31 11.420.42 11.510.57
Controls 11.010.39 11.420.37 11.540.38 11.650.45
Anti-Thy-1.1 
 Vitamin D3 11.490.41 11.620.42 12.000.51 12.010.32
Vitamin D3 11.450.35 11.500.39 11.890.54 12.210.47
Phosphate mg/dL
Anti-Thy-1.1 3.60.5 3.80.6 4.00.6 3.50.6
Controls 3.50.6 3.70.9 3.80.6 3.80.3
Anti-Thy-1.1 
 Vitamin D3 3.70.9 3.80.5 4.10.5 4.10.9
Vitamin D3 3.60.3 3.80.5 4.00.8 3.90.4
Data regarding renal function, calcium and phosphate in all groups of rats are included. No significant variations were observed in calcium phosphate balance in
the experimental time.
a A significant increase of plasma BUN and creatinine was observed in nephritic rats (Anti-Thy-1.1) at day 4 (P  0.01 vs. the other groups)
introduce DNA breaks in all nuclei were used as positive
controls.
Calculation of cell number was performed by the in-
vestigators in a blinded fashion using coded samples until
the analysis was complete. Results were expressed as the
number of positive cells per glomerular cross section;
the percentage of positive glomeruli for each kidney
cross section was also calculated.
Statistical analysis
Analysis of variance and the Student–Neumann–
Fig. 3. No significant difference in immunofluorescence staining forKeul’s t test were used for statistical analysis. Values are
anti-rat C3 antibody was detected in glomeruli of rats injected withexpressed as mean  SD; the null hypothesis was re- anti-Thy-1.1 antibodies (anti-Thy-1.1; A) and of rats injected with anti-
jected when P  0.05. Thy-1.1 antibodies treated with 1,25(OH)2D3 (anti-Thy-1.1 
 vitamin
D3; B).
RESULTS
IL-6 urinary excretionEffects of 1,25(OH)2D3 pretreatment on proteinuria
The results regarding IL-6 urinary excretion in theDuring the course of the study, no animals showed
four groups of rats are depicted in Figure 2B. IL-6 urinaryclinically adverse effects. There was no difference in
excretion was significantly increased in nephritic rats atbody weight, fluid intake, or urinary volume among the
days 2, 3, 4, and 7 versus all groups.four groups of rats.
1,25(OH)2D3 treatment significantly inhibited the en-As shown in Figure 2A, the four groups had similar
hanced IL-6 urinary excretion observed in nephritic rats
levels of protein excretion before the injection of anti- at days 2, 3, 4, and 7 (Fig. 2B).
Thy-1.1 antibodies. Compared with control rats, anti-
Thy-1.1 nephritic rats (anti-Thy-1.1 group) demonstrated Renal function, serum calcium and phosphate,
urinary calciumfrank proteinuria from day 2 to day 14. In nephritic rats
in which 1,25(OH)2D3 was administered [anti-Thy-1.1 Data regarding renal function at days 0, 4, 7, and 14
treated with 1,25(OH)2D3 group], a significant reduction in all groups of rats are shown in Table 1. No significant
variations in serum calcium and phosphate were ob-of proteinuria was detected.
Panichi et al: Vitamin D3 and anti-Thy-1.1 nephritis 91
Table 2. Glomerular size
Day 1 Day 4 Day 7 Day 14
Controls 236.3030.90 239.4029.11 243.7133.20 246.4231.63
Controls 
 vitamin D3 234.2125.26 236.0022.11 240.9127.33 245.1233.81
Anti-Thy-1.1 252.6237.09ab 249.2936.32ab 283.6138.11ab 267.4246.33ab
Anti-Thy-1.1 
 vitamin D3 233.3531.52 247.0135.70a 261.0848.20a 231.7231.08a
The size of glomeruli was evaluated in  by measuring cross-sectional diameter. The mean glomerular diameter of rats receiving anti-Thy-1.1 antibody (Anti-
Thy-1.1), but not of rats treated with 1,25(OH)2D3 (Anti-Thy-1.1 
 vitamin D3) was significantly increased in respect to the controls at days 1, 4, 7 and 14 after Ab
anti-Thy-1.1 administration.
a P  0.01 vs. control groups
b P  0.01 vs. anti-Thy-1.1 
 vitamin D3
Fig. 4. A peak of neutrophil accumulation
was detectable at day 4 in rats receiving anti-
Thy-1.1 antibody (anti-Thy-1.1) by morpho-
metric analysis of sections stained with His48
(20 12 His48-positive cells/glomerulus; *P
0.001 vs. control groups). Symbols are: ()
anti-Thy-1.1; () anti-Thy-1.1 
 vitamin D3;
() controls; () controls 
 vitamin D3. The
number of neutrophils decreased in the fol-
lowing days (12  2 His48-positive cells/glo-
merulus at day 7 and 10  1 His48-positive
cells/glomerulus at day 14; *P 0.001 vs. con-
trols groups). Treatment with 1,25(OH)2D3
(anti-Thy-1.1 
 vitamin D3) completely abro-
gated the glomerular accumulation of His48-
positive cells (§P  0.001 nephritic rats vs.
anti-Thy-1.1 
 vitamin D3).
served at day 14 in 1,25(OH)2D3-treated rats. Urinary creased in respect to the controls at days 1, 4, 7, and 14
(Table 2). Moreover, the mean glomerular diameter ofcalcium (expressed as mg calcium/mg creatininuria) at
day 14 showed no significant variation in all groups of rats treated with 1,25(OH)2D3 [anti-Thy-1.1 treated with
1,25(OH)2D3 group] was significantly lower then thatrats: The mean values  SD were, respectively, 0.47 
0.20 in the control group, 0.54  0.29 in the control 
 of rats injected with anti-Thy-1.1 antibody (anti-Thy-1.1
group). In untreated nephritic rats (anti-Thy-1.1 group)1,25(OH)2D3 group, 0.45  0.26 in the anti-Thy-1.1
at day 4, most glomeruli showed mesangial cells destruc-group, and 0.60  0.28 in the anti-Thy-1.1 treated with
tion and aneurysms of the capillary loops.1,25(OH)2D3 group. A significant increase of plasma
Infiltration of inflammatory cells. A peak of neutrophilblood urea nitrogen and creatinine was observed in ne-
accumulation was detectable at day 4 by morphometricphritic rats (anti-Thy-1.1 group) at day 4 (P  0.01 vs.
analysis of sections stained with His48 (Fig. 4). The num-controls). In contrast, no variations in renal function
ber of neutrophils decreased in the following days.were observed in nephritic rats treated with 1,25(OH)2D3
ED1-positive monocytes were significantly increased[anti-Thy-1.1 treated with 1,25(OH)2D3 group].
one day after injection of anti-Thy-1.1 antibodies, and
Morphological studies after a transient reduction, their number peaked at day
7 and decreased thereafter (Fig. 5C). Treatment withImmunofluorescence studies. No significant difference
in immunofluorescence staining for anti-Thy-1.1 anti- 1,25(OH)2D3 [anti-Thy-1.1 treated with 1,25(OH)2D3
group] completely abrogated the glomerular accumula-bodies and complement was detected in glomeruli of
rats injected with anti-Thy-1.1 antibodies and treated tion of His48-positive polymorphonuclear cells. Whereas
1,25(OH)2D3 did not significantly reduce the early accu-[anti-Thy-1.1 treated with 1,25(OH)2D3 group] or un-
treated with 1,25(OH)2D3 (anti-Thy-1.1 group; Fig. 3). mulation of ED1-positive monocytes observed at day 1,
the number of glomerular monocytes was significantlyGlomerular size and morphological findings. The size
of glomeruli was evaluated by measuring the cross-sec- reduced at day 7 (Fig. 5D).
Apoptosis and mesangial cell proliferation. By TUNEL,tional diameter. The mean glomerular diameter of rats
receiving anti-Thy-1.1 antibody (anti-Thy-1.1 group) the first peak of apoptotic cells was detected at day 4,
concomitantly with morphological aspects of mesangio-but not of rats treated with 1,25(OH)2D3 [anti-Thy-1.1
treated with 1,25(OH)2D3 group] was significantly in- lysis (Fig. 6). Figure 7 shows that the number of apoptotic
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into the glomeruli [21, 22]. Early mesangiolysis is fol-
lowed by mesangial proliferation mediated by a complex
interplay of several proinflammatory mediators and
growth factors. The mesangial alterations are followed
by a recovery phase that is characterized by capillary
angiogenesis, matrix remodeling, and the restoration of
normal glomerular cellularity by apoptosis of inflamma-
tory and excess glomerular mesangial cells [23, 24].
This study provides evidence that 1,25(OH)2D3 can
attenuate proteinuria, inflammation, and glomerular hy-
percellularity in anti-Thy-1.1 nephritis.
Few studies have investigated the effects of 1,25(OH)2D3
on the development of glomerular pathology. Branis-
teanu et al induced active Heymann nephritis in Lewis
rats treated with 1,25(OH)2D3 [17]. In their model,
1,25(OH)2D3 (0.5 g/kg body wt) was administered on
alternate days during the first 13 days after active immu-
nization significantly reduced proteinuria. This reduction
of proteinuria was comparable to our observation in rats
treated with CsA (20 mg/kg) on alternate days. These
results were interpreted as an immunosuppressive effect
of 1,25(OH)2D3, which is supported by several studies
indicating an immunosuppressive activity of 1,25(OH)2D3
[3–7]. The inhibition of dendritic cell differentiation andFig. 5. Immunohistochemical detection of ED1-positive monocytes in
maturation, as well as the modulation of their activationa kidney section of anti-Thy-1.1 nephritic rats (anti-Thy-1.1; A and C)
and anti-Thy-1.1 nephritic rats treated with 1,25(OH)2D3 (anti- and survival leading to T-cell hyporesponsiveness may ex-
Thy-1.1 
 vitamin D3; B and D) four days (A and B) and seven days plain the immunosuppressive activity of 1,25(OH)2D3 [9].(C and D) after antibody injection. ED1-positive nuclei are stained in
Moreover, in a rat model of subtotal nephrectomy,black. The number of glomerular monocytes was significantly reduced
at days 4 and 7 in the anti-Thy-1.1 
 vitamin D3 group. Schwarz et al demonstrated that 1,25(OH)2D3 possesses
an antiproliferative action during the compensatory
growth of nephrons in response to subtotal nephrectomy
[18]. In their model, 1,25(OH)2D3 reduces renal cell pro-cells was reduced in rats treated with 1,25(OH)2D3 [anti-
liferation and glomerular growth as well as glomerulo-Thy-1.1 treated with 1,25(OH)2D3 group] in respect to
sclerosis and albuminuria as indicators of progressivenephritic rats (anti-Thy-1.1 group). Apoptosis was reduced
glomerular damage. They concluded that 1,25(OH)2D3at day 7, and a second peak was detected at day 14 (Fig.
has antiproliferative actions during the compensatory6) concomitantly with the reduction of mesangial cell
growth of nephrons in response to subtotal nephrectomy,proliferation detected by PCNA (Figs. 8 and 9 A, C).
and that this effect is independent of parathyroid hor-Mesangial proliferation peaked at day 7 and then de-
mone (PTH).creased thereafter. The early apoptotic response detected
The results of our study provide evidence thatat day 4 was completely abrogated in 1,25(OH)2D3-treated
1,25(OH)2D3 also may display an anti-inflammatory ac-rats (anti-Thy-1.1 treated with 1,25(OH)2D3 group; Figs.
tion that protects the model of anti-Thy-1.1–induced ne-6 and 7B). The extent of proliferation was reduced over-
phritis against immune-mediated glomerular injury, byall in the treated group (Figs. 5B and 9 B, D). However,
using a passive administration of an antibody that isat day 14, the extent of apoptosis was not different in
reactive with mesangial cells.treated [anti-Thy-1.1 treated with 1,25(OH)2D3 group]
In this model, an antibody and complement-depen-or untreated nephritic rats (anti-Thy-1.1 group).
dent early mesangiolysis occurs [22]. We also observed
an increased apoptosis in concomitance with mesangio-
DISCUSSION lysis. These events were associated with an early recruit-
ment of inflammatory cells, which include a transientRat mesangial cells express the thymocyte anti-Thy-1.1.
The administration of anti-Thy-1.1 antibodies induces a accumulation of neutrophils and a more persistent infil-
tration of monocytes.mesangial proliferative glomerulonephritis [19, 20]. The
early pathological events are characterized by mesangio- The role of neutrophils in the process of glomerular
damage in this model is considered to be of minor rele-lysis and accumulation within hours after antibody injec-
tion of polymorphonuclear neutrophils and monocytes vance, as shown by neutrophil depletion studies [25]. In
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Fig. 6. As shown by TUNEL, a first peak of
apoptotic cells was detected at day 4 in the
anti-Thy-1.1 group (*P  0.01 nephritic rats
vs. control groups). Symbols are: () anti-
Thy-1.1; () anti-Thy-1.1 
 vitamin D3; ()
controls; () controls 
 vitamin D3. Apopto-
sis was reduced at day 7, and a second peak
was detected at day 14 concomitantly with
the reduction of mesangial cell proliferation
detected by PCNA (*P  0.01 nephritic rats
vs. control groups). The early apoptotic re-
sponse detected at day 4 was completely abro-
gated in 1,25(OH)2D3-treated rats (anti-
Thy-1.1
 vitamin D3, §P 0.01 nephritic rats
vs. anti-Thy-1.1 
 vitamin D3). However, at
14, the extent of apoptosis was not different
in treated (anti-Thy-1.1 
 vitamin D3) or un-
treated nephritic rats (anti-Thy-1.1), sug-
gesting that the apoptosis involved in the re-
gression of glomerular proliferation was not
affected by treatment with 1,25(OH)2D3.
prevents the early accumulation of neutrophils, sug-
gesting an action at the step of recruitment of these cells.
In contrast, 1,25(OH)2D3 does not abrogate the early
accumulation of monocytes but favors their disappear-
ance from glomeruli, suggesting that its action is that of
cell activation rather than recruitment. A decreased pro-
duction of pro-inflammatory cytokine, which is suggested
by the early reduction of IL-6, may reflect an inhibitory
action of 1,25(OH)2D3 on monocyte activation, such as
that previously seen for dendritic cells [9]. These obser-
Fig. 7. Detection of apoptotic cells by TUNEL in kidney sections of
vations should stimulate further in vitro studies to inves-anti-Thy-1.1 nephritic rats (anti-Thy-1.1; A) and anti-Thy-1.1 nephritic
rats treated with 1,25(OH)2D3 (anti-Thy-1.1 
 vitamin D3; B) four tigate the differential effects of 1,25(OH)2D3 on different
days after antibody injection. Positive nuclei are stained in black. An populations of inflammatory cells.
important reduction of apoptotic cells was detected in the anti-Thy-1.1

In agreement with the results obtained by Schwarzvitamin D3-treated rat.
et al in a model of subtotal nephrectomy, a significant
inhibition of mesangial proliferation in rats treated with
1,25(OH)2D3 was observed [18]. Indeed, as detected by
contrast, macrophages are considered instrumental in PCNA staining, glomerular proliferation was reduced in
the development of glomerular alterations, since they Thy-1.1 nephritic rats treated with 1,25(OH)2D3. These
produce both nitric oxide (NO) and reactive oxygen spe- antiproliferative effects may depend either on a direct
cies that may induce apoptosis and mediate mesangio- action of 1,25(OH)2D3 on mesangial cells (abstract; Ooi
lysis [26]. Moreover, secretion from macrophages of et al, J Am Soc Nephrol 102:2107, 1998) [27] or on the
growth factors and cytokines may contribute to mesan- inhibitory effects on monocyte accumulation and/or acti-
gial cell proliferation and accumulation of mesangial ma- vation. Several studies suggest that inhibition of monocyte
trix that occurs in the late stage of anti-Thy-1.1–induced accumulation prevents mesangial cells proliferation and
glomerular injury. matrix expansion in anti-Thy-1.1 glomerular injury [28].
The results of the present study demonstrate that the The anti-Thy-1.1 model is transient, and glomeruli can
antiproteinuric effect of 1,25(OH)2D3 is associated with recover from the massive cell proliferation and mesangial
a reduction in mesangiolysis and early apoptosis, and in matrix expansion. Shimizu et al showed that in anti-
the glomerular inflammatory process. Indeed, apoptotic Thy-1.1 glomerulonephritis, apoptosis has a critical role
cells detected by TUNEL were significantly inhibited at in the regression of glomerular injury leading to the
day 4 in rats treated with 1,25(OH)2D3. Moreover, the disappearance of the inflammatory cells and reduction
inhibition of urinary excretion of IL-6 and the accumula- in number of proliferating mesangial cells [24]. In recent
tion of neutrophils and monocytes within the glomeruli years, apoptosis has been implicated in the resolution of
suggest that 1,25(OH)2D3 affects glomerular inflamma- the inflammatory response. Darby, Skalli, and Gabbiani
reported that myofibroblasts can undergo apoptosis dur-tion in Thy-1.1-induced injury. In particular, 1,25(OH)2D3
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Fig. 8. An important reduction of mesangial
cell proliferation assessed by proliferating cell
nuclear antigen (PCNA) was detected in anti-
Thy-1.1 
 vitamin D3-treated rats versus ne-
phritic rats after 4, 7, and 14 days from anti-
body injection. Symbols are: () anti-Thy-1.1;
() anti-Thy-1.1 
 vitamin D3; () controls;
() controls
 vitamin D3. Mesangial prolifer-
ation peaked at day 7 and decreased to day
14 (*P  0.01 vs. control groups; §P  0.05
vs. anti-Thy-1.1 
 1,25(OH)2D3).
served in the early apoptotic changes (day 4) was not
dependent on an anti-apoptotic action, but rather on the
anti-inflammatory action of the drug.
In conclusion, our study suggests that 1,25(OH)2D3
attenuates proteinuria as well as morphological and func-
tional alterations occurring in the anti-Thy-1.1–induced
GN as a result of an anti-inflammatory action. Future
studies are needed to evaluate the mechanisms by which
1,25(OH)2D3 is able to reduce inflammatory cell infiltra-
tion and glomerular proliferation, and accelerate the res-
olution of glomerular injury.
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